비스테로이드성 항염증제(NSAIDs) 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the NSAIDs market size was valued at USD 24.11 billion in 2025 and estimated to grow from USD 25.48 billion in 2026 to reach USD 33.57 billion by 2031, at a CAGR of 5.67% during the forecast period (2026-2031).

This report Segments the Industry Into by Route of Administration (Oral, Parenteral, and More), Drug Class (Non-Selective COX Inhibitors, COX-2 Selective Inhibitors), Application (Arthritis, Migraine & Headache, and More), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends and Insights

Rising Global Burden of Chronic Pain & Inflammatory Disorders

Chronic pain affects more than 100 million adults worldwide, and osteoarthritis prevalence is set to climb sharply by 2050, reinforcing a structural need for anti-inflammatory drugs. Broader diagnostic capabilities in emerging economies widen the patient pool, while governments classify chronic pain as its own condition, supporting reimbursement for long-term NSAID therapy. Workforce productivity losses tied to untreated pain further justify coverage expansions. As a result, the NSAIDs market secures a stable demand base that transcends economic cycles.

Preference for NSAIDs Over Opioids & Acetaminophen

Clinical trials show an ibuprofen-acetaminophen regimen can equal hydrocodone's pain relief with none of the addiction risk. US and EU prescribing guidelines now advise non-opioid first-line therapy, propelling formulary placement of NSAIDs. Because these products also treat inflammation, they out-perform acetaminophen in arthritis and sports injuries. Payers see cost savings versus opioid misuse expenses, reinforcing guideline adoption. This shift repositions the NSAIDs market as the cornerstone of moderate-pain management.

GI & Cardiovascular Adverse Events Prompting Regulatory Warnings

The FDA and European Medicines Agency (EMA) now require boxed warnings covering cardiovascular, GI, and rare dermatologic events. High-dose NSAID courses in ankylosing spondylitis raise ischemic heart disease and stroke risk according to longitudinal cohort analyses. Clinicians screen patients more rigorously and limit duration, trimming prescription volumes. Added monitoring inflates treatment costs, weighing on the NSAIDs market despite unflagging underlying demand.

Other drivers and restraints analyzed in the detailed report include:

1. Growing OTC Availability & Self-Medication Culture
2. Fixed-Dose-Combination Topical Gels Improving GI Safety
3. Patent Cliffs & Price Erosion for Blockbuster Brands

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Oral products kept 55.92% of NSAIDs market size in 2025 because of physician familiarity and patient convenience. Topical options, however, climb at 6.18% CAGR as risk-averse prescribers recommend localized therapy for osteoarthritis and soft-tissue injuries. Advanced hydrogels now match oral efficacy without increasing GI or cardiovascular events.

Fixed-dose combination patches embed permeation enhancers that sustain release for up to 12 hours, reducing dosing frequency and boosting adherence. Regulatory guidance encourages topical NSAIDs in older adults with comorbidities. Consequently, manufacturers expand plant capacity for gels and sprays to capture incremental volumes in the NSAIDs market.

Non-selective inhibitors retained the largest 61.77% slice of NSAIDs market size in 2025 by virtue of cost and broad indication labeling. COX-2 agents escalate at 6.32% CAGR as new evidence refines cardiovascular risk assessments and highlights GI protection. Emerging candidates optimize selectivity ratios and half-lives to widen their therapeutic window.

Pipeline products also aim for dual-target inhibition, modulating prostaglandin and leukotriene pathways simultaneously to tackle inflammation with fewer side effects. If late-stage trials confirm benefit, non-selective dominance could erode, reshaping drug-class revenue mix within the NSAIDs market.

Complete Report Scope:

• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Others
• By Drug Class
  • Non-selective COX Inhibitors
  • COX-2 Selective Inhibitors
• By Application
  • Arthritis
  • Migraine & Headache
  • Ophthalmic Conditions
  • Fever & Flu
  • Dysmenorrhea
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.35% of revenue in 2025, supported by high healthcare outlays and opioid-replacement policies that prioritize NSAID prescriptions. Regulatory frameworks are robust, and insurers push cost-effective generics, creating both stability and price pressure in this zone of the NSAIDs market.

Asia-Pacific records the fastest 6.29% CAGR through 2031 as populations age and middle-class consumers seek affordable pain relief. Local manufacturers scale production, and governments integrate essential NSAIDs into reimbursement lists, accelerating access. OTC use is widespread, yet physician visits per capita are rising, bringing more diagnosed arthritis and migraine cases into formal care.

Europe retains sizeable volume anchored by universal health systems, yet strict EMA evaluations slow new launches and emphasize pharmacovigilance. Emerging regions in the Middle East, Africa, and South America gain momentum as infrastructure improves. Multinationals partner with domestic distributors to navigate regulatory nuance and economic swings while unlocking incremental demand in the global NSAIDs market.

1. Pfizer
2. Bayer
3. Johnson & Johnson (McNeil)
4. Haleon plc
5. Reckitt Benckiser Group
6. Sanofi
7. Horizon Therapeutics
8. Sun Pharmaceuticals Industries
9. Assertio
10. Perrigo Company
11. Iroko Pharmaceuticals
12. Viatris
13. Novartis
14. Dr. Reddy's Laboratories Ltd
15. Teva Pharmaceutical Industries
16. Boehringer Ingelheim
17. Abbvie
18. Endo International
19. Hikma Pharmaceuticals
20. Orion

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Burden of Chronic Pain & Inflammatory Disorders
  • 4.2.2 Preference for NSAIDs Over Opioids & Acetaminophen
  • 4.2.3 Growing OTC Availability & Self-medication Culture
  • 4.2.4 Emergence of Fixed-dose-combination Topical Gels Improving GI Safety
  • 4.2.5 AI-driven Drug-repositioning Accelerating Low-cost Reformulations
  • 4.2.6 Expanding Applications in Specialized Therapeutic Areas
• 4.3 Market Restraints
  • 4.3.1 GI & Cardiovascular Adverse Events Prompting Regulatory Warnings
  • 4.3.2 Patent Cliffs & Price Erosion for Blockbuster Brands
  • 4.3.3 Increasing Healthcare Cost Pressures and Generic Competition
  • 4.3.4 Growing Awareness of Drug Interactions and Contraindications
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Route of Administration
  • 5.1.1 Oral
  • 5.1.2 Parenteral
  • 5.1.3 Topical
  • 5.1.4 Others
• 5.2 By Drug Class
  • 5.2.1 Non-selective COX Inhibitors
  • 5.2.2 COX-2 Selective Inhibitors
• 5.3 By Application
  • 5.3.1 Arthritis
  • 5.3.2 Migraine & Headache
  • 5.3.3 Ophthalmic Conditions
  • 5.3.4 Fever & Flu
  • 5.3.5 Dysmenorrhea
  • 5.3.6 Others
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 E-commerce
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia & New Zealand
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles
  • 6.4.1 Pfizer Inc.
  • 6.4.2 Bayer AG
  • 6.4.3 Johnson & Johnson (McNeil)
  • 6.4.4 Haleon plc
  • 6.4.5 Reckitt Benckiser Group plc
  • 6.4.6 Sanofi SA
  • 6.4.7 Horizon Therapeutics plc
  • 6.4.8 Sun Pharmaceutical Industries Ltd
  • 6.4.9 Assertio Holdings Inc.
  • 6.4.10 Perrigo Company plc
  • 6.4.11 Iroko Pharmaceuticals Inc.
  • 6.4.12 Viatris Inc.
  • 6.4.13 Novartis AG
  • 6.4.14 Dr. Reddy's Laboratories Ltd
  • 6.4.15 Teva Pharmaceutical Industries Ltd
  • 6.4.16 Boehringer Ingelheim GmbH
  • 6.4.17 AbbVie Inc.
  • 6.4.18 Endo International plc
  • 6.4.19 Hikma Pharmaceuticals plc
  • 6.4.20 Orion Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment